|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
It is shown that the TNF signaling pathway plays a role through the process of DN progression and adipocytokine signaling pathway is uniquely enriched in ESRD.Molecules, such as TNF, IL6, SOD2, etc. are very important for DN progression, among which, it seems that "AGER" plays a pivotal role in the mechanism.
|
31409386 |
2019 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Receptor for advanced glycation end-products (RAGE) is involved in the pathogenesis of diabetic nephropathy.
|
30393200 |
2019 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings suggest that this AG, acting as a RAGE antagonist, is a promising agent for the prevention and treatment of DN.
|
30672023 |
2019 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To determine the mechanism(s) of protection, we found that whilst deficiency of TLR2, TLR4 or RAGE afforded partial protection from development of DN, over-expression of esRAGE provided additional protection in TLR2<sup>-/-</sup>, modest protection against podocyte damage only in TLR4<sup>-/-</sup> and no protection in RAGE<sup>-/-</sup> diabetic mice, suggesting the protection provided by esRAGE was primarily through interruption of RAGE and TLR4 pathways.
|
29844451 |
2018 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Contribution of myo-inositol oxygenase in AGE:RAGE-mediated renal tubulointerstitial injury in the context of diabetic nephropathy.
|
28931523 |
2018 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
The findings suggest that continuous infusion of RAGE-aptamer could attenuate the development and progression of experimental diabetic nephropathy by blocking the AGE-RAGE axis.
|
28385802 |
2017 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Common variants in RAGE are strongly associated with plasma sRAGE level, which is associated with DKD.
|
27448675 |
2017 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis indicated that the RAGE gene -429CC genotype might be a risk factor for DN in patients with type 2 diabetes.
|
25707513 |
2015 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
We also outline novel treatments targeting the AGE-RAGE axis and specific Nox isoforms, which hold great promise in attenuating the development of diabetes-associated atherosclerosis and diabetic nephropathy.
|
26323666 |
2015 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our study indicated that the 2184A/G polymorphism in the RAGE gene was significantly associated with diabetic nephropathy in Chinese Han patients with type 2 diabetes.
|
26770981 |
2015 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Thus, activation of the RAGE by advanced glycation end products or other ligands suppresses NIPP1 expression in diabetic nephropathy, contributes to podocyte hypertrophy, and glomerular inflammation.
|
24476693 |
2014 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggested that there might be no association of RAGE gene polymorphisms (Gly82Ser, 1704G/T, 429T/C) with T2DM, DR and DN risk.
|
22475522 |
2012 |
|
Diabetic Nephropathy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study is to examine whether PPARδ alters the expression of the receptor for advanced glycation end products (RAGE) and downstream pro-inflammatory cytokines in diabetic nephropathy.
|
21458563 |
2011 |
|
Diabetic Nephropathy
|
0.300 |
Therapeutic
|
disease |
RGD |
The protective effect of Salvia miltiorrhiza in an animal model of early experimentally induced diabetic nephropathy.
|
21856399 |
2011 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The 63 bp del-/+ genotype of the RAGE gene has a marginal benefit on the cardiovascular event-free survival in subjects with diabetic nephropathy.
|
20040351 |
2010 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
RGD |
GSPE reduced the expression of RAGE (p < 0.01) and CTGF (p < 0.01) in the kidney, which were contributing to reversal of extracellular matrix accumulation in DN.
|
19142024 |
2009 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In a logistic regression analysis, the LTA but not the AGER polymorphism was associated with diabetic nephropathy (OR 2.55[1.11-5.86], p = 0.03).
|
18575614 |
2008 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In multi-locus analysis, six SNPs exhibited a significant association with DN: four SNPs on chromosome 6p (AGER 2184A/G, LTA 252A/G, EDN1 8002G/A and AGER -429T/C) and two SNPs on chromosome 7q (NOS3 774C/T and NOS3 E298D), omnibus p = 0.033.
|
17345061 |
2007 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients.
|
16969646 |
2006 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus.
|
15790669 |
2005 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Receptor for advanced glycation end products is a promising target of diabetic nephropathy.
|
16037279 |
2005 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus.
|
15790669 |
2005 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
We conclude, that patients with type 2 diabetes and the 63bp deletion in the promoter of RAGE seem to be protected from diabetic nephropathy.
|
15052533 |
2004 |
|
Diabetic Nephropathy
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
We studied the relation between the genotypes of the NADPH p22phox C242T and RAGE G1704T polymorphisms and the development of diabetic nephropathy in type 2 diabetic patients.
|
14747204 |
2004 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy.
|
15180953 |
2004 |